Media  Kit

For Media Inquiries, please contact:

Christine Lindenboom
VP, Investor Relations & Corporate Communications
media@alnylam.com

 

Fact Sheets

  • Alnylam Corporate Overview (PDF)
  • RNA Interference (RNAi) and the Future of Drug Development (U.S. Version) (PDF)
  • Hereditary ATTR Amyloidosis (hATTR amyloidosis) Backgrounder (PDF)
  • APOLLO Phase 3 Clinical Trial Overview (U.S. Version) (PDF)
  • Acute Hepatic Porphyria (AHP) Backgrounder (PDF)
  • ENVISION Phase 3 Clinical Trial Overview (PDF)
  • Givosiran Backgrounder (PDF)
  • ONPATTROTM (patisiran) Product Fact Sheet (U.S. Version) (PDF)
  • Lumasiran ILLUMINATE-A Phase 3 Clinical Trial Overview (PDF)
  • Lumasiran Backgrounder (PDF)
  • Primary Hyperoxaluria Type 1 Backgrounder (PDF)

 

Photos

Executive Officers

 

Illustrations

 

Logos

SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.